Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (23472)	7/24/1998 10:24:00 AM
From: tonyt	Respond to of 32384

Interesting how you won't make a definitive statement. I guess when you made that statement you didn't believe that LGND would fall below $12. Looks like you were wrong again! BTW, looks like you'll be able to "buy more on the dips today" Good Luck, --Tony

To: Machaon who wrote (23472)	7/24/1998 10:27:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bob, LGND also has a cancer (almost certainly breast) program with LLY to look at combining SERMs, such as Evista, with Rexinoids, such as Targretin, LGD1268, or LGD1324. These combinations will almost certainly have prevention applications for breast cancer as well as osteoporosis.

To: Machaon who wrote (23472)	7/24/1998 10:57:00 AM
From: Henry Niman	Respond to of 32384

On Wednesday the Financial times brought up a GLX/SBH merger again, and today the WSJ has an extensive article on MRK, including more merger speculation. Details in merger table at home.att.net